Activists in Berlin stage picket condemning Obama’s foreign policyWorld January 19, 21:17
Russian regulator promises to respond to any US restrictions of RT channelRussian Politics & Diplomacy January 19, 21:09
FIFA: Over 82,400 ticket requests applied globally for 2017 Confederations Cup in RussiaSport January 19, 20:17
Russia stands for developing legal tool to fight cyber hooliganismRussian Politics & Diplomacy January 19, 20:00
Russia is developing advanced hypersonic weapons — ministryMilitary & Defense January 19, 19:50
Former USSR leader receives Lithuanian court’s summons as witness in case over 1991 eventsWorld January 19, 19:29
FIDE chief says he plans to seek US entry after President-elect Trump’s inaugurationSport January 19, 18:56
Russian economy minister: Results of 2016 demonstrated adjustment to cheap oil, sanctionsBusiness & Economy January 19, 18:44
Russia ready to welcome Trump at economic forum in St. Petersburg — first deputy PMBusiness & Economy January 19, 18:29
LONDON, June 14. /TASS/. Russian tennis star Maria Sharapova said she would file an appeal with the Court of Arbitration for Sports (CAS) against her two-year suspension, imposed last week by the International Tennis Federation’s (ITF) Tribunal over anti-doping violations, Britain’s web portal Sky News reported on Tuesday.
In early March, Sharapova announced that her doping tests revealed the presence of performance enhancing drug meldonium in the body system. Following the announcement, former World’s No. 1 was provisionally suspended from all tennis-related activities.
The drug meldonium (mildronate) was included in the list of preparations banned by WADA from January 1, 2016. The presence of the meldonium substance in the athlete’s blood during and between competitions is a violation of anti-doping rules. The substance belongs to S4 class on the WADA blacklist (hormones and metabolic modulators).
WADA announced on April 13 that the concentration of less than one microgram of meldonium in the body system of an athlete, whose doping tests were conducted before March 1, was acceptable.